Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure at one year compared with patients who did not take the drug, according to a study presented at the American College of Cardiology’s Annual Scientific Session.